Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

Stopped early · Phase 2 · Has a placebo group

Conditions studied: NEUROFIBROMATOSIS 1

In brief

The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.

Key facts

Study ID

NCT02728388

Run by

Donald Basel

People needed

30

Starts

2016-09-16

Expected to finish

2026-03-28

Last updated by the study team

2026-07-10

Who can join

Age: 14 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is 14 years or older.
• Diagnosed NF1, determined by American Academy of Neurology Guidelines (see Diagnosis section).
• Tumor Location: cutaneous, trunk, or limbs only.
• Tumor Type: superficial dermal neurofibromas ≤4mm deep.
• Patient has provided written informed consent.
• Patient is willing to and can comply with study follow-up requirements.
• Absence of any other malignancy.

You may not qualify if…

• Life expectancy less than 3 years.
• Pregnancy.
• Cutaneous photosensitivity to the wavelengths used to active PDT.
• A diagnosis of porphyria.
• Allergy to aminolevulinic acid or any of the topical solution vehicle components.
• Previous chemotherapy within 6 weeks of proposed PDT.
• Other concurrent tumor therapy.

Where it is running

• Donald G Basel — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.